BRPI0911991A2 - derivados de 5-hidroximetil-oxazolidin-2-ona para o tratamento de doenças intestinais bacterianas - Google Patents

derivados de 5-hidroximetil-oxazolidin-2-ona para o tratamento de doenças intestinais bacterianas

Info

Publication number
BRPI0911991A2
BRPI0911991A2 BRPI0911991A BRPI0911991A BRPI0911991A2 BR PI0911991 A2 BRPI0911991 A2 BR PI0911991A2 BR PI0911991 A BRPI0911991 A BR PI0911991A BR PI0911991 A BRPI0911991 A BR PI0911991A BR PI0911991 A2 BRPI0911991 A2 BR PI0911991A2
Authority
BR
Brazil
Prior art keywords
derivatives
treatment
intestinal disease
hydroxymethyl oxazolidin
bacterial intestinal
Prior art date
Application number
BRPI0911991A
Other languages
English (en)
Inventor
Hubschwerlen Christian
Locher Hans
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40955145&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0911991(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0911991A2 publication Critical patent/BRPI0911991A2/pt
Publication of BRPI0911991B1 publication Critical patent/BRPI0911991B1/pt
Publication of BRPI0911991B8 publication Critical patent/BRPI0911991B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0911991A 2008-05-09 2009-05-08 derivados de 5-hidroximetil-oxazolidin-2-ona para o tratamento de doenças intestinais bacterianas BRPI0911991B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2008/051854 2008-05-09
IBIB2008/051854 2008-05-09
PCT/IB2009/051896 WO2009136379A1 (en) 2008-05-09 2009-05-08 5-hydroxymethyl-oxazolidin-2-one derivatives for treating bacterial intestinal diseases

Publications (3)

Publication Number Publication Date
BRPI0911991A2 true BRPI0911991A2 (pt) 2018-02-27
BRPI0911991B1 BRPI0911991B1 (pt) 2020-09-15
BRPI0911991B8 BRPI0911991B8 (pt) 2021-05-25

Family

ID=40955145

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911991A BRPI0911991B8 (pt) 2008-05-09 2009-05-08 derivados de 5-hidroximetil-oxazolidin-2-ona para o tratamento de doenças intestinais bacterianas

Country Status (24)

Country Link
EP (1) EP2296651B1 (pt)
JP (1) JP4819980B2 (pt)
KR (1) KR101283222B1 (pt)
CN (1) CN102014903B (pt)
AR (1) AR071762A1 (pt)
AU (1) AU2009245351B2 (pt)
BR (1) BRPI0911991B8 (pt)
CA (1) CA2723232C (pt)
CY (1) CY1113197T1 (pt)
DK (1) DK2296651T3 (pt)
ES (1) ES2390405T3 (pt)
HR (1) HRP20120791T1 (pt)
IL (1) IL209105A0 (pt)
MA (1) MA32375B1 (pt)
MX (1) MX2010011918A (pt)
MY (1) MY156304A (pt)
NZ (1) NZ589734A (pt)
PL (1) PL2296651T3 (pt)
PT (1) PT2296651E (pt)
RU (1) RU2527769C2 (pt)
SI (1) SI2296651T1 (pt)
TW (1) TWI447115B (pt)
WO (1) WO2009136379A1 (pt)
ZA (1) ZA201008841B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031443A1 (en) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
MXPA05011654A (es) 2003-04-30 2005-12-15 Morphochem Ag Komb Chemie Uso de antibioticos hibridos de oxazolidinona-quinolina para el tratamiento del antrax y de otras infecciones.
DE10340485B4 (de) 2003-09-03 2015-05-13 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Verfahren zur Herstellung von Oxazolidinon-Chinolon Hybriden
US8158797B2 (en) 2003-12-18 2012-04-17 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Oxazolidinone-quinolone hybrid antibiotics
ES2310299T5 (es) † 2003-12-18 2014-02-10 Morphochem Aktiengesellschaft für kombinatorische Chemie Antibióticos híbridos a base de oxazolidinona-quinolona
EP3003289B1 (en) 2013-05-28 2019-02-20 Morphochem Aktiengesellschaft für kombinatorische Chemie Administration of oxazolidinone-quinolone hybrid antibacterials
RU2675847C2 (ru) * 2013-05-28 2018-12-25 Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми Комбинированные терапевтические средства, содержащие оксазолидинон-хинолоны, предназначенные для лечения бактериальных инфекций
US10087171B2 (en) 2016-12-19 2018-10-02 Actelion Pharmaceuticals Ltd Crystalline forms of cadazolid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1156597A3 (ru) * 1982-04-28 1985-05-15 Е.И.Дюпон Де Немур Энд Компани (Фирма) Способ получени производных 3-( @ -алкилсульфонилфенил)оксазолидинона или их фармацевтически приемлемых кислотно-аддитивных солей
US4461773A (en) * 1982-09-15 1984-07-24 E. I. Dupont De Nemours And Company P-Oxooxazolidinylbenzene compounds as antibacterial agents
EP1349853B1 (en) * 2000-12-21 2006-03-08 Pharmacia & Upjohn Company LLC Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
ES2186550B2 (es) * 2001-06-27 2003-11-16 Vita Lab Nuevos derivados de oxazolidinonas como antibacterianos.
WO2003031443A1 (en) * 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
MXPA05011654A (es) * 2003-04-30 2005-12-15 Morphochem Ag Komb Chemie Uso de antibioticos hibridos de oxazolidinona-quinolina para el tratamiento del antrax y de otras infecciones.
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
CL2007003232A1 (es) * 2006-11-10 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas.

Also Published As

Publication number Publication date
SI2296651T1 (sl) 2012-10-30
MA32375B1 (fr) 2011-06-01
MX2010011918A (es) 2010-11-26
ZA201008841B (en) 2012-05-30
PL2296651T3 (pl) 2012-12-31
MY156304A (en) 2016-01-29
PT2296651E (pt) 2012-10-01
HK1155086A1 (en) 2012-05-11
CA2723232A1 (en) 2009-11-12
TW200948808A (en) 2009-12-01
HRP20120791T1 (hr) 2012-11-30
WO2009136379A1 (en) 2009-11-12
AU2009245351A1 (en) 2009-11-12
EP2296651A1 (en) 2011-03-23
BRPI0911991B1 (pt) 2020-09-15
CY1113197T1 (el) 2016-04-13
AR071762A1 (es) 2010-07-14
JP4819980B2 (ja) 2011-11-24
IL209105A0 (en) 2016-09-29
RU2010149994A (ru) 2012-06-20
EP2296651B1 (en) 2012-07-18
DK2296651T3 (da) 2012-09-24
CN102014903A (zh) 2011-04-13
JP2011519914A (ja) 2011-07-14
RU2527769C2 (ru) 2014-09-10
AU2009245351B2 (en) 2015-01-22
NZ589734A (en) 2012-11-30
TWI447115B (zh) 2014-08-01
CN102014903B (zh) 2013-07-10
BRPI0911991B8 (pt) 2021-05-25
CA2723232C (en) 2016-08-02
KR101283222B1 (ko) 2013-07-11
ES2390405T3 (es) 2012-11-12
KR20100137569A (ko) 2010-12-30

Similar Documents

Publication Publication Date Title
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
PT2504005E (pt) Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI0814624A2 (pt) Tratamento de doença neurodegenerativa progresiva com ibudilaste
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
ES2898695T8 (es) Derivados de benzoxaborol para el tratamiento de infecciones bacterianas
BRPI0819471A2 (pt) câmara de tratamento ultrassônico para preparar emulsões
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0819475A2 (pt) Câmara de tratamento ultrassônico para preparar formulações antimicrobianas
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI0810727A2 (pt) Dispositivo para a aplicação oral de uma substância.
BRPI0813670A2 (pt) Compostos para tratamento
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0811919A2 (pt) Medicamento para tratamento do mal de alzheimer
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
DOP2010000373A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2826 DE 06-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.